The aHUS alliance’s mission highlights the importance of patient organisations reaching out and connecting with and supporting aHUS clinical researchers, who in turn may reciprocate.
The pages of this website reflects the extent to which connections and collaborations have been established between the alliance and many of the worlds’ leading aHUS experts for the benefit of the world’s aHUS patients.
aHUS expertise takes time to build up. Decades in fact. And over that time the batons of knowledge are passed from one generation to the next . Some clinicians stand out as being pivotal to that process.
Professor Bernard S Kaplan, latterly of the Children’s Hospital of Philadelphia , is one such aHUS expert. Now retired , South African born Prof Kaplan is a link between the founder of our disease , Prof Conrad Von Gasser, and the “genetic generation” of aHUS researchers.
Bernard S Kaplan on right of photo.
In the 1970s to 1990s he was part of a movement to separate the “familial” / “recurrent” version of Von Gassers “syndromes” ( the other being found to be linked to e.coli) and look towards the Complement System and hypothesise genetic causal reasons within it This version was to become known as aHUS ,or Complement Mediated Haemolytic Uraemic Syndrome
For the first aHUS Awareness Day ( note – 24 September 2019 is the next Awareness Day) in September 2015 Prof Kaplan wrote a special account of the journey of aHUS from the Children’s Hospital in Zurich , Switzerland, to the pioneers of aHUS Complement genetic research. This article was a tribute to Von Gasser , 60 years to the day on 20 September 1955 when the term Haemolytic Uraemic Syndrome appeared in print for the first time. The article is reproduced in full below*.
He also edited a book in which Von Gassers’ collaborators , Emile Gautier and Rudolph Siebemann, wrote about the 1954 research and the diagnosis and naming of HUS. Now out of print, Prof Kaplan has given the alliance permission to put a copy of the chapter about the “Birth of HUS” in the alliance website library (in the info centre) . Click here to read it.
If the aHUS patient community were ever to have a “ wall of honour” to those who have added to the knowledge of aHUS for the benefit of aHUS patients , Prof. Von Gasser would surely be on it . So too would Bernard S Kaplan.
Bernard S. Kaplan, MB BCh, FAAP, Division of Pediatric Nephrology,The Children’s Hospital of Philadelphia, Professor of Pediatrics and Medicine,The Perelman School of Medicine at The University of Pennsylvania Philadelphia, PA 19066.
Gasser’s seminal paper entitled Hamolytisch-uramiche Syndrome [HUS] was published on September 20th 1955 . In 1977 he had written to us requesting copies of our papers on HUS [this was before the days of the Internet]. I sent him reprints and invited him to visit the Montreal Children’s Hospital where, in 1978 [Fig 1], he gave a memorable lecture on his syndrome. Professor Gasser, a pediatric hematologist, was a gracious, thoughtful and generous man. He told us about his interest in the anemias and how he had begun to notice that some children with acute anemia had bizarre shaped erythrocytes. These fragmented red blood cells were called schistocytes. He and his co-worker, to whom he gave unstinting credit, selected five cases, which, in addition to evidence of hemolysis were severely ill with thrombocytopenia, acute renal failure and cerebral symptoms. All of the five patients died. Four had vomiting and diarrhea and one had pneumonia. Gasser believed, and continued to stress in his lecture as well as in a chapter in 1978, that the essential feature that distinguished HUS from Thrombotic Thrombocytopenia [TTP] was the severe renal involvement in the former, and the multi-organ involvement in the latter.
Conrad Von Gasser in centre of group with Bernard S Kaplan to the immediate right.
When I met Professor Gasser in 1978 he congratulated Keith Drummond [my Montreal mentor] and me for our editorial titled The hemolytic-uremic syndrome is a syndrome . He gently chided us because he pointed out that his original paper was not entitled Hemolytic Uremic Syndrome but Hemolytic Uremic Syndromes. In German, he explained, syndrom is the singular for syndrome. However, he was generous in his praise for the fact that we had restated his concept.
Conrad von Gasser presented me with a Swiss cowbell [Fig 2] and asked me to ring it whenever the first International Symposium on HUS was to be held. In September 1982 I wrote to Prof. Gasser to inform him of my intention to dedicate the first symposium on HUS at an international conference to him. He died a month before my letter reached his office. And so, in Hannover, Germany, I rang the bell in his honor and in his memory in 1983 . At The Hospital for Sick Children, Toronto, on September 9th 2015, I presented a lecture entitled Re-imagining the Hemolytic Uremic Syndrome at Grand Rounds and talked again about the cowbell.
Von Gasser’s Swiss Cowbell
Professor Gasser in his initial and subsequent publications gave a name to his syndrome, or as he stressed, syndromes. He and his colleagues differentiated HUS from TTP [although it took about 50 years for this to become accepted fully], described what we now recognize as S. pneumoniae HUS, and familial HUS, and recurrent HUS. Although many of their patients had diarrhea and vomiting Gasser et al did not recognize the diarrhea as a prodromal feature of HUS.
In 1992 we were honored when Professor E. Gautier and Professor R.E. Siebenmann contributed a chapter to our book Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. As the co-authors of Gasser’s original paper they were in a unique position to describe The Birth of the Hemolytic Uremic Syndrome .
In regard to HUS, few came before Gasser but large numbers came after him. Joan Wagner, a South African pediatrician, while working at Great Ormond Street Children’s Hospital, may have been the first to report a case of HUS in an infant under the heading Acute Tubular Necrosis with Anemia . There are now 6904 listings on HUS in PubMed. Madame Rene Habib made major contributions to our understanding of the pathology of HUS.
After Gasser et al. the second seminal contribution was Carlos Gianantonio’s description of the Diarrheal form of HUS [Fig 3]. His team advocated using early peritoneal dialysis and described the long-term histopathological outcomes of diarrheal HUS .
Barnard and Kibel, 1965, were the first to differentiate between typical and atypical HUS . They noted that Diarrhoea of early onset was present in 10 of our 11 cases, and this has also been stressed in many others… but is not mentioned in the series by Gasser et al. Our atypical case, they noted, gave no history of diarrhoea. They also speculated in 1968 that HUS was caused by an E. coli infection . Gervais et al, in 1971, used the term atypical  thereby predating that of Barratt et al’s classification of HUS into two groups – typical (epidemic, D+, diarrhea-associated) and atypical HUS (non-diarrhea associated, D- HUS) . Neither group referred to Barnard and Kibel’s paper.
In 1978 we suggested that there was an inherited type of HUS that differed from an acquired type of HUS . I subsequently drew attention to Hemolytic uremic syndrome with recurrent episodes: An important subset and I noted that these patients might have combinations of recurrent episodes and complement deficiency. In 1992 I predicted that most all of these will [would] turn out to be genetic.
Several months after Gasser et al’s original paper McKay and Wahle reported a case of Epidemic gastroenteritis due to Escherichia coli O111 B4 . This predated by 28 years the most important seminal contribution by Karmali et al . Karmali et al. showed that E. coli 0157:H7 producing shiga toxin is the most important cause of HUS.
The third momentous discovery was the finding of mutations in the factor H gene that led to decreased concentrations of factor H in the alternative pathway of complement  and modestly noted that in light of these findings and previous reports of HUS in patients with factor H deficiency, we postulate that abnormalities of factor H may be involved in the etiology of HUS.
These abnormalities in the regulation of complement activity eventually led to a profound change in the treatment of atypical HUS with eculizumab .